Metabolic derangements of skeletal muscle from a murine model of glioma cachexia

被引:31
作者
Cui, Pengfei [1 ]
Shao, Wei [2 ]
Huang, Caihua [3 ]
Wu, Chang-Jer [4 ]
Jiang, Bin [5 ]
Lin, Donghai [1 ]
机构
[1] Xiamen Univ, Dept Chem Biol, Coll Chem & Chem Engn, 422 Siming South Rd, Xiamen 361005, Peoples R China
[2] Xiamen Univ, Affiliated Chenggong Hosp, Dept Pathol, Xiamen, Peoples R China
[3] Xiamen Univ Technol, Dept Phys Educ, 600 Ligong Rd, Xiamen 361024, Peoples R China
[4] Natl Taiwan Ocean Univ, Dept Food Sci, Keelung, Taiwan
[5] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen, Peoples R China
基金
中国国家自然科学基金;
关键词
Glioma cachexia; Malignant grades; Animal model; Muscle atrophy; Metabolic derangements; Skeletal muscle metabolism; ACTIVATED PROTEIN-KINASE; CANCER CACHEXIA; UBIQUITIN LIGASES; WEIGHT-LOSS; ATROPHY; PATHWAY; SERUM; MECHANISMS; EXPRESSION; REGULATOR;
D O I
10.1186/s13395-018-0188-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
BackgroundCachexia is a complex metabolic disorder and muscle atrophy syndrome, impacting 80% patients with advanced cancers. Malignant glioma is considered to be one of the deadliest human cancers, accounting for about 60% of all primary brain tumors. However, cachexia symptoms induced by glioma have received little attention. This work aims to explore skeletal muscle atrophy in orthotopic glioma murine models.MethodsBALB/c nude mice were orthotopicly implanted with normal glial (HEB) and glioma (WHO II CHG5 and WHO IV U87) cells. Cachexia symptoms of mice were depicted by phenotypic, histopathologic, physiological, and biochemical analyses. Muscle atrophy-related proteins were examined by western blot, and the involved signaling pathways were analyzed. NMR-based metabolomic analysis was applied to profile metabolic derangements in the skeletal muscle, including multivariate statistical analysis, characteristic metabolite identification, and metabolic pathway analysis.ResultsCompared with controls, mice implanted with glioma cells exhibit typical cachexia symptoms, indicating a high correlation with the malignant grades of glioma. U87 mice develop cachexia much earlier and more severe than CHG5 mice. The glioma-bearing mice showed significantly decreased skeletal muscle mass and strength, which were associated with suppressed AKT, activated AMPK, FOXO, Atrogin1, and LC3. Interestingly, expressions of MuRF1, MyoD1, and eIF3f were not significantly changed. Consistently, metabolomic analyses elucidate pronounced metabolic derangements in cachectic gastrocnemius relative to controls. Glucose, glycerol, and 3-hydroxybutyrate were remarkably downregulated, whereas glutamate, arginine, leucine, and isoleucine were upregulated in cachectic gastrocnemius. Furthermore, U87 mice showed more characteristic metabolites and more disturbed metabolic pathways including glucose and lipid metabolism, protein catabolism, anabolism, and citric acid cycle anaplerotic.ConclusionsThis study demonstrates for the first time that the orthotopic glioma murine model developed here exhibits high fidelity of cachexia manifestations in two malignant grades of glioma. Signaling pathway analysis in combination with metabolomic analysis provides significant insights into the complex pathophysiology of glioma cachexia and expands understanding of the molecular mechanisms underlying muscle atrophy.
引用
收藏
页数:13
相关论文
共 53 条
[1]   Mechanism of increased lipolysis in cancer cachexia [J].
Agustsson, Thorhallur ;
Ryden, Mikael ;
Hoffstedt, Johan ;
van Harmelen, Vanessa ;
Dicker, Andrea ;
Laurencikiene, Jurga ;
Isaksson, Bengt ;
Permert, Johan ;
Arner, Peter .
CANCER RESEARCH, 2007, 67 (11) :5531-5537
[2]   Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting [J].
Antunes, Diana ;
Padrao, Ana Isabel ;
Maciel, Elisabete ;
Santinha, Deolinda ;
Oliveira, Paula ;
Vitorino, Rui ;
Moreira-Goncalves, Daniel ;
Colaco, Bruno ;
Pires, Maria Joao ;
Nunes, Claudia ;
Santos, Lucio L. ;
Amado, Francisco ;
Duarte, Jose Alberto ;
Domingues, Maria Rosario ;
Ferreira, Rita .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2014, 1841 (06) :896-905
[3]   Cancer cachexia: understanding the molecular basis [J].
Argiles, Josep M. ;
Busquets, Silvia ;
Stemmler, Britta ;
Lopez-Soriano, Francisco J. .
NATURE REVIEWS CANCER, 2014, 14 (11) :754-762
[4]   Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts [J].
Beckonert, Olaf ;
Keun, Hector C. ;
Ebbels, Timothy M. D. ;
Bundy, Jacob G. ;
Holmes, Elaine ;
Lindon, John C. ;
Nicholson, Jeremy K. .
NATURE PROTOCOLS, 2007, 2 (11) :2692-2703
[5]   Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo [J].
Bodine, SC ;
Stitt, TN ;
Gonzalez, M ;
Kline, WO ;
Stover, GL ;
Bauerlein, R ;
Zlotchenko, E ;
Scrimgeour, A ;
Lawrence, JC ;
Glass, DJ ;
Yancopoulos, GD .
NATURE CELL BIOLOGY, 2001, 3 (11) :1014-1019
[6]   Identification of ubiquitin ligases required for skeletal muscle atrophy [J].
Bodine, SC ;
Latres, E ;
Baumhueter, S ;
Lai, VKM ;
Nunez, L ;
Clarke, BA ;
Poueymirou, WT ;
Panaro, FJ ;
Na, EQ ;
Dharmarajan, K ;
Pan, ZQ ;
Valenzuela, DM ;
DeChiara, TM ;
Stitt, TN ;
Yancopoulos, GD ;
Glass, DJ .
SCIENCE, 2001, 294 (5547) :1704-1708
[7]   Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1 [J].
Bodine, Sue C. ;
Baehr, Leslie M. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2014, 307 (06) :E469-E484
[8]   AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. [J].
Bolster, DR ;
Crozier, SJ ;
Kimball, SR ;
Jefferson, LS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :23977-23980
[9]   Cellular and molecular mechanisms of muscle atrophy [J].
Bonaldo, Paolo ;
Sandri, Marco .
DISEASE MODELS & MECHANISMS, 2013, 6 (01) :25-39
[10]   Skeletal muscle in cancer cachexia: The ideal target of drug therapy [J].
Bossola, Maurizio ;
Pacelli, Fabio ;
Tortorelli, Antonio ;
Rosa, Fausto ;
Doglietto, Giovan Battista .
CURRENT CANCER DRUG TARGETS, 2008, 8 (04) :285-298